Skip to main content

Table 1 Patient demographics and baseline clinical characteristics by dose level

From: STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Characteristic

2 mg/kg (n = 10)

3 mg/kg (n = 20)

Median age, y (range)

69 (23–83)

65 (22–81)

Male, n (%)

8 (80)

10 (50)

White, n (%)

8 (80)

20 (100)

ECOG performance status, n (%)

 0

4 (40)

3 (15)

 1

6 (60)

15 (75)

 2

 

2 (10)

Disease stage, n (%)

 I

0

2 (10)

 II

1 (10)

3 (15)

 III

4 (40)

3 (15)

 IV

5 (50)

12 (60)

Prior treatment with radiation therapy, n (%)

3 (30)

6 (30)

Prior treatment with systemic therapy, n (%)

10 (100)

20 (100)

 Median number of prior regimens (range)

4.5 (1–8)

3.5 (1–9)

Prior treatment with surgery, n (%)

3 (30)

3 (15)

History of cancer(s) other than current cancer, n (%)

5 (50)

3 (15)